• Trulieve highlighted its NYSE listing under ticker TRLV, following federal rescheduling of medical marijuana to Schedule III in April 2026.
• Corporate restructuring deconsolidated mixed medical and adult-use operations into “Harvest”; Trulieve retains a 90% economic interest.
• Core consolidated footprint: 206 DEA-registered medical dispensaries, 3.5 million square feet of cultivation and processing capacity across Florida, Georgia, Pennsylvania, West Virginia.
• 2025 results: USD 1.2 billion revenue, 60% gross margin, USD 273 million cash flow from operations.
• Key growth drivers: Georgia program expansion with pharmacy distribution from July 1, 2026; Texas buildout pending final license approval expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trulieve Cannabis Corp. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.